Edwards' Winning Heart Valve Strategy

Edwards Lifesciences' strategy of divesting slow-growing businesses and focusing on the relatively underserved niche of late-stage (or what the company now calls advancing stage) cardiovascular disease appears to be paying off. Now the leader in the heart valve market, the company believes that the pressures cardiac surgeons are feeling, coupled with the introduction of devices like drug-eluting stents, might open up new opportunities as surgeons turn to other ways to add value to the treatment of patients with cardiovascular disease.

When Baxter International Inc. announced in July 1999 its plan to follow the spin-off of its hospital supply division, Allegiance Corp. , three years earlier with the spin-off of its cardiovascular group, which became Edwards Lifesciences Corp. [See Deal], company officials hoped the move would produce results similar to the success Guidant Corp. achieved following its split from Eli Lilly & Co. But where Guidant focused on more well-established market segments such as interventional cardiology and cardiac rhythm management (CRM), Edwards concentrated on the relatively under-served niche of late-stage, or what the company now calls advancing stage, cardiovascular disease.

The strategy appears to be paying off, as Edwards' officials report the company has become the leader in the heart...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.